Cancer BiologybioRxivPreprint
PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis
G. Napoletani, S. S. Soldan, T. Kannan…·I. Tempera
This study shows that PARP1 inhibition reduces EBV-driven lymphoma progression by disrupting the EBNA2/MYC axis in a mouse model.
DOI 10.1101/2023.07.05.547847